Biomarker ID | 648 |
PMID | 21520154 |
Year | 2011 |
Biomarker | PSMA + PSGR + PCA3 + PSA |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Urine |
Subjects | Humans |
Regulation | Differentially Expressed |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(FOLH1) :-One-carbon metabolism,TNF-alpha effects on cytokine activity, cell motility, and apoptosis, T cell receptor regulation of apoptosis Pathways Include(O51E2) :- Olfactory transduction,Signaling by GPCR Pathways Include(KLK3):- ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
Experiment | (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml |
Type of Biomarker | Diagnostic |
Cohort | Samples for Benign (n=54) and PCA (n=28) were taken into account for this study such that they had PSA in the range 4-10ng/ml. |
Senstivity | NA |
Specificity | NA |
AUC | 0.77 |
Accuracy | NA |
Level Of Significance | NA |
Method Used | qPCR |
Clinical | No |
Remarks | Briefly, 50% of the sample was used as a training set to compute a ROC curve. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | FOLH1, OR51E2, PCA3, KLK3 |